Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint
Phase III clinical study (Study Protocol No.: KN026-003) of Anbenitamab (‘‘KN026’’), co-developed by Shanghai JMT-BIO Technology Co., Ltd. (‘‘JMT-BIO’’), a subsidiary of the Company, and Jiangsu Alphamab Oncology Co., Ltd., in combination with the Group’s self-developed Docetaxel for Injection (Albumin-bound) (‘‘HB1801’’) for the first-line treatment of HER2-positive advanced breast cancer has successfully met the pre-specified primary endpoint of progression-free survival (‘‘PFS’’) as assessed by the Independent Data Monitoring Committee (the ‘‘IDMC’’), yielding results that are both statistically significant and clinically meaningful, with a favourable safety profile.
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines